TrialInternational journal of hematology2021

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Koji Izutsu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.